Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 result for ta446

  1. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

    This guidance has been updated and replaced by NICE technology appraisal guidance 524.